Author

Drew C. Deniger

ORCID 0000-0002-9299-9688Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

Alexandre ReubeniD· 1 shared Amanda MontoyaiD· 1 shared Anika PateliD· 1 shared Bo JiangiD· 1 shared Changsheng XingiD· 1 shared Emane Rose AssitaiD· 1 shared Emily BontekoeiD· 1 shared Gregory A. LizeeiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

Alexandre ReubenORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

HER2 mutation-derived neoantigens in NSCLC as actionable targets for TCR therapy

Amanda Montoya, Hui Nie, Peixin Jiang, Jared K. Slone, Yulia V. Shulga, Anika Patel, Prashant S. Menon, Isabella Polic, Emily Bontekoe, Lingzhi Hong, Minying Zhang, Emane Rose Assita, Sarah Forward, Changsheng Xing, Bo Jiang, , Alexandre Reuben

The paper identifies TCRs targeting HER2 mutations in NSCLC, showing they recognize mutant epitopes and maintain cytotoxic activity, offering a potential immunotherapy strategy.

bioRxiv · Aug 4, 2026 · PreprintImmunology